BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 16757685)

  • 1. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.
    Ishii T; Bruno E; Hoffman R; Xu M
    Blood; 2006 Nov; 108(9):3128-34. PubMed ID: 16757685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
    Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
    Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycythemia vera is not initiated by JAK2V617F mutation.
    Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
    Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis.
    Delhommeau F; Dupont S; Tonetti C; Massé A; Godin I; Le Couedic JP; Debili N; Saulnier P; Casadevall N; Vainchenker W; Giraudier S
    Blood; 2007 Jan; 109(1):71-7. PubMed ID: 16954506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.
    Jamieson CH; Gotlib J; Durocher JA; Chao MP; Mariappan MR; Lay M; Jones C; Zehnder JL; Lilleberg SL; Weissman IL
    Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6224-9. PubMed ID: 16603627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.
    Lippert E; Boissinot M; Kralovics R; Girodon F; Dobo I; Praloran V; Boiret-Dupré N; Skoda RC; Hermouet S
    Blood; 2006 Sep; 108(6):1865-7. PubMed ID: 16728702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
    PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera.
    Swierczek SI; Yoon D; Bellanné-Chantelot C; Kim SJ; Saint-Martin C; Delhommeau F; Najman A; Prchal JT
    Haematologica; 2011 May; 96(5):775-8. PubMed ID: 21273266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
    Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C
    Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique.
    Leszczynska A; Grzenkowicz-Wydra J; Chmielewska-Gorycka L; Bieniaszewska M; Hellmann A
    Acta Haematol; 2016; 136(2):123-8. PubMed ID: 27410038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2 V617F mutation is rare in idiopathic erythrocytosis: a difference from polycythemia vera.
    Yoshinaga K; Mori N; Wang YH; Tomita K; Shiseki M; Motoji T
    Int J Hematol; 2008 Jul; 88(1):82-87. PubMed ID: 18528646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations.
    Li S; Kralovics R; De Libero G; Theocharides A; Gisslinger H; Skoda RC
    Blood; 2008 Apr; 111(7):3863-6. PubMed ID: 18195094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic JAK-2 V617F Mutational Analysis in Polycythemia Rubra Vera: a Tertiary Care Center Experience.
    Sultan S; Irfan SM; Khan SR
    Asian Pac J Cancer Prev; 2016; 17(3):1053-5. PubMed ID: 27039724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.
    Rapado I; Albizua E; Ayala R; Hernández JA; Garcia-Alonso L; Grande S; Gallardo M; Gilsanz F; Martinez-Lopez J
    Ann Hematol; 2008 Sep; 87(9):741-9. PubMed ID: 18575865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.
    Berkofsky-Fessler W; Buzzai M; Kim MK; Fruchtman S; Najfeld V; Min DJ; Costa FF; Bischof JM; Soares MB; McConnell MJ; Zhang W; Levine R; Gilliland DG; Calogero R; Licht JD
    Clin Cancer Res; 2010 Sep; 16(17):4339-52. PubMed ID: 20601445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P; Hanrahan V; Baker B; Romeril K
    Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.